Library

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (5)
  • 1940-1944
  • 1999  (5)
  • Biochemistry and Biotechnology
  • Ras
Material
Years
  • 1995-1999  (5)
  • 1940-1944
Year
  • 1
    ISSN: 1432-0843
    Keywords: Key words SCH 59228 ; Orally bioavailable ; Tricyclic farnesyl-transferase-inhibitor ; Ras ; Xenograft
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The products of the Ha-, Ki-, and N-ras proto-oncogenes comprise a family of 21 kDa guanine nucleotide-binding proteins which play a crucial role in growth factor signal transduction and in the control of cellular proliferation and differentiation. Activating mutations in the ras oncogenes occur in a wide variety of human tumors. Ras proteins undergo a series of posttranslational processing events. The first modification is addition of the 15-carbon isoprene, farnesyl, to a Cys residue near the carboxy-terminus of Ras. Prenylation allows the Ras oncoprotein to localize to the plasma membrane where it can initiate downstream signalling events leading to cellular transformation. Inhibitors of the enzyme which catalyzes this step, farnesyl protein transferase (FPT), are a potential class of novel anticancer drugs which interfere with Ras function. SCH 59228 is a tricyclic FPT inhibitor which inhibits the farnesylation of purified Ha-Ras with an IC50 of 95 nM and blocks the processing of Ha-Ras in Cos cells with an IC50 of 0.6  M. SCH 59228 has favorable pharmacokinetic properties upon oral dosing in nude mice. The in vivo efficacy of SCH 59228 was evaluated using a panel of tumor models grown in nude mice. These included several rodent fibroblast lines expressing mutationally-activated (val12) forms of the Ha-Ras oncogene. In some cases, these proteins contain their native C-terminal sequence (CVLS) which directs farnesylation. In one model, the C-terminal sequence was altered to CVLL, making the expressed protein a substrate for a distinct prenyl transferase, geranylgeranyl protein transferase-1. When dosed orally at 10 and 50 mg/kg (four times a day, 7 days a week) SCH 59228 significantly inhibited tumor growth of cells expressing farnesylated Ha-Ras in a dose-dependent manner; over 90% growth inhibition was observed at the 50 mg/kg dose. Tumor growth of cells expressing the geranylgeranylated form of Ha-Ras was less potently inhibited. Growth of tumors derived from a rodent fibroblast line expressing activated Ki-Ras containing its native C-terminal sequence (CVIM), which preferentially directs farnesylation, was also inhibited by SCH 59228. Inhibition in the Ki-Ras model was less than that observed in the Ha-Ras model. In contrast, tumors derived from cells transformed with the mos oncogene were not significantly inhibited even at the highest dose level. SCH 59228 also significantly and dose-dependently inhibited the growth of human colon adenocarcinoma DLD-1 xenografts (which express activated Ki-ras). These results indicate that SCH 59228 possesses in vivo antitumor activity upon oral dosing in tumor models expressing activated ras oncogenes. This is the first report of oral antitumor activity with an FPT inhibitor. These results are discussed in light of recent observations on alternative prenylation of some Ras isoforms.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1617-4623
    Keywords: Key wordsColletotrichum trifolii ; Growth polarity ; Ras ; Signal transduction
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology
    Notes: Abstract Ras is a low-molecular-weight guanine nucleotide (GDP/GTP)-binding protein that transduces signals for growth and differentiation in eukaryotes. In mammals, the importance of Ras in regulating growth is underscored by the observation that activating mutations in ras genes are found in many animal tumors. Colletotrichum trifolii is a filamentous fungal pathogen of alfalfa which causes anthracnose disease. To investigate signaling pathways that regulate growth and development in this fungus, a gene encoding a Ras homolog (CT-Ras) was cloned from C. trifolii. CT-Ras exhibited extensive amino acid similarity to Ras proteins from higher and lower eukaryotes. A single amino acid change resulting in mutationally activated CT-Ras induced cellular transformation of mouse (NIH 3T3) fibroblasts and tumor formation in nu/nu mice. In Colletotrichum, mutationally activated CT-Ras induced abnormal hyphal proliferation and defects in polarized growth, and significantly reduced differentiation in a nutrient-dependent manner. These results show that C. trifolii Ras is a functional growth regulator in both mammals and fungi, and demonstrate that proper regulation of Ras is required for normal fungal growth and development.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Cell biology and toxicology 15 (1999), S. 345-358 
    ISSN: 1573-6822
    Keywords: Ras ; GTPase ; oncogenesis ; signal transduction ; anticancer drugs
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine
    Notes: Abstract Ras proteins are molecular switches that constitute a pivotal element in the control of cellular responses to many incoming signals, and in particular mitogenic stimulations. They act through multiple effector pathways that carry out the biological functions of Ras in cells. Since mutations that constitutively activate Ras proteins have been found in a high proportion of human malignancies and participate in oncogenesis, a number of therapeutic anticancer strategies aimed against the activity or action of Ras proteins have been developed. This paper reviews the principal aspects of the Ras signaling pathway and describes some of the attempts to develop antitumor drugs based on this concept.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Investigational new drugs 17 (1999), S. 241-258 
    ISSN: 1573-0646
    Keywords: Ras ; Raf kinase ; MEK ; farnesyl protein transferase (FPT)
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract The year 2000 will be a significant date for the field of Ras-related therapies since numerous agents will have Phase II clinical efficacy data maturing to provide proof of principle for this cancer treatment strategy. These data will also provide an important milestone for the cancer research community since these molecules represent a small vanguard of oncology drug discovery projects predicated on molecular targets. We can only hope that these agents are a successful harbinger for the formidable number of targeted therapies that will be entering development pipelines in the coming years.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Perspectives in drug discovery and design 15-16 (1999), S. 295-311 
    ISSN: 1573-9023
    Keywords: mitogenic signaling ; proliferation ; Ras ; receptor tyrosine kinase ; Src
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Abstract Potassium channels, especially small and intermediate conductance KCa channels, have important roles in controlling cell proliferation and differentiation. Thus far regulation of these channels is reported to be primarily at the level of expression, in response to activation of the central growth regulatory signaling pathway (i.e., growth factor receptor tyrosine kinase/Ras/Raf/MEK/ERK). Therefore, the function and regulation of these cell growth-associated channels must be viewed differently from that of channels which govern electrical signaling in excitable cells, and which are typically studied in terms of their transient modulation by G-protein coupled receptors. Although there are suggestions that potassium channels also contribute to growth regulation in excitable cells, a coherent picture of this role in these systems is still emerging. For fibroblasts and T-lymphocytes, it is clear that growth factor and oncogenic upregulation of a unique KCa channel (or possibly KCa channel class) is stimulatory for cell proliferation and activation, respectively. This mitogenic channel has a single channel conductance in the range of 33–39 pS, it is charybdotoxin-sensitive and apamin-insensitive, and its gating is voltage-independent. Recent cloning data suggest that the KCa channel (or channel class) described for fibroblasts and T-cells has a widespread distribution in other mitogenically active (non-neuronal) tissues. A number of studies are now underway to understand the physiology, pharmacology and regulation of this channel. Further, it is now critical to determine how KCa activity integrates into the signaling pathways which convey growth regulatory information from the cell membrane, to the nucleus, and then to the ultimate effectors for cell proliferation or differentiation. It has also become apparent that these growth regulatory signaling systems interact with other channel types, affecting channel densities at the level of expression, and channel activities at the level of gating modulation. Therefore, it seems most appropriate to view ion channel function in the context of how it contributes to and is affected by both cell growth activity, and the biochemical signaling systems linked to growth control.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...